Advertisement

Drugs

, Volume 76, Issue 18, pp 1787–1792 | Cite as

Etelcalcetide: First Global Approval

  • Hannah A. Blair
AdisInsight Report

Abstract

Etelcalcetide (Parsabiv™) is a novel second generation calcimimetic agent developed by Amgen for the treatment of secondary hyperparathyroidism (SHPT), a complication of chronic kidney disease (CKD). Etelcalcetide reduces circulating levels of parathyroid hormone and calcium by binding directly to the calcium-sensing receptor. Intravenous etelcalcetide has been approved in the EU for the treatment of SHPT in adult patients with CKD on haemodialysis therapy. Regulatory applications for etelcalcetide in SHPT are also under review in the USA and Japan. This article summarizes the milestones in the development of etelcalcetide leading to this first global approval for the treatment of SHPT.

Keywords

Chronic Kidney Disease Cinacalcet Serum iPTH Parathyroid Gland Hyperplasia Adynamic Bone Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. H. A. Blair is a salaried employee of Adis, Springer SBM.

References

  1. 1.
    Cozzolino M, Tomlinson J, Walsh L, et al. Emerging drugs for secondary hyperparathyroidism. Expert Opin Emerg Drugs. 2015;20(2):197–208.CrossRefPubMedGoogle Scholar
  2. 2.
    Rodriguez M, Goodman WG, Liakopoulos V, et al. The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10 year evidence review. Semin Dial. 2015;28(5):497–507.CrossRefPubMedGoogle Scholar
  3. 3.
    Amgen. European Commission approves Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults on hemodialysis [media release]. 11 Nov 2016. http://www.amgen.com.
  4. 4.
    Committee for Medicinal Products for Human Use (CHMP). Parsabiv: etelcalcetide—summary of opinion (initial authorisation). 2016. http://www.ema.europa.eu. Accessed 19 Oct 2016.
  5. 5.
    Amgen. Amgen submits marketing authorization application for novel intravenous calcimimetic etelcalcetide (AMG 416) to the European Medicines Agency [media release]. 2 Sep 2015. http://www.amgen.com.
  6. 6.
    Amgen. Amgen provides update on status of Parsabiv™ (etelcalcetide) New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) [media release]. 24 Aug 2016. http://www.amgen.com.
  7. 7.
    Ono Pharmaceutical. ONO submits manufacturing and marketing approval application in Japan for “etelcalcetide hydrochloride” (ONO-5163), a calcimimetic agent, for secondary hyperparathyroidism in patients on hemodialysis [media release]. 14 Jan 2016. http://www.ono.co.jp.
  8. 8.
    Ono Pharmaceutical. Ono enters into license agreement with KAI Pharmaceuticals, Inc. for KAI 4169 [media release]. 15 Sep 2011. http://www.ono.co.jp.
  9. 9.
    Amgen. Amgen completes acquisition of KAI Pharmaceuticals [media release]. 5 Jul 2012. http://www.amgen.com.
  10. 10.
    Walter S, Baruch A, Dong J, et al. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther. 2013;346(2):229–40.CrossRefPubMedGoogle Scholar
  11. 11.
    Alexander ST, Hunter T, Walter S, et al. Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol. 2015;88(5):853–65.CrossRefPubMedGoogle Scholar
  12. 12.
    Walter S, Baruch A, Alexander ST, et al. Comparison of AMG 416 and cinacalcet in rodent models of uremia. BMC Nephrol. 2014;15(1):81.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Martin KJ, Bell G, Pickthorn K, et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant. 2014;29(2):385–92.CrossRefPubMedGoogle Scholar
  14. 14.
    Shen J, Vick A, Pickthorn K, et al. The PK/PD relationship of calcimimetic KAI-4169 following single-dose administration to healthy young males [abstract no. P1-236 ]. In: The Endocrine Society’s 93rd Annual Meeting and Expo. 2011.Google Scholar
  15. 15.
    Martin KJ, Pickthorn K, Huang S, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014;85(1):191–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Yokoyama K, Fukagawa M, Shigematsu T, et al. A novel intravenous calcimimetic, ONO-5163 (etelcalcetide): a multicenter, single and multiple dose study in Japanese hemodialysis patients with secondary hyperparathyroidism [abstract no. MP368]. Nephrol Dial Transplant. 2016;31(Suppl 1):i462.Google Scholar
  17. 17.
    Shen J, Xiao J, Pickthorn K, et al. A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. J Clin Pharmacol. 2014;54(10):1125–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Chen P, Melhem M, Xiao J, et al. Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol. 2015;55(6):620–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Subramanian R, Zhu X, Hock MB, et al. Pharmacokinetics, biotransformation, and excretion of [(14)C]etelcalcetide (AMG 416) following a single microtracer intravenous dose in patients with chronic kidney disease on hemodialysis. Clin Pharmacokinet. 2016. doi: 10.1007/s40262-016-0433-0.PubMedGoogle Scholar
  20. 20.
    Edson KZ, Wu BM, Iyer A, et al. Determination of etelcalcetide biotransformation and hemodialysis kinetics to guide the timing of its dosing. Kidney International Reports. 2016;1(1):24–33.CrossRefGoogle Scholar
  21. 21.
    Subramanian R, Zhu X, Kerr SJ, et al. Nonclinical pharmacokinetics, disposition, and drug-drug interaction potential of a novel d-amino acid peptide agonist of the calcium-sensing receptor AMG 416 (etelcalcetide). Drug Metab Dispos. 2016;44(8):1319–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Cunningham J, Trial Steering Committee. A long acting intravenous calcimimetic (AMG416) for secondary hyperparathyroidism (SHPT) in haemodialysed patients [abstract no. 15-LBA-3558]. In: 52nd ERA-EDTA Congress. 2015.Google Scholar
  23. 23.
    Bushinsky DA, Block GA, Cheng S, et al. One year efficacy and safety of intravenous (IV) etelcalcetide (AMG 416) in patients on hemodialysis (HD) with secondary hyperparathyroidism (SHPT) [abstract no. SO030]. Nephrol Dial Transplant. 2016;31(Suppl 1):i13–4.Google Scholar
  24. 24.
    Fukagawa M, Yokoyama K, Shigematsu T, et al. Efficacy and safety of a novel intravenous calcimimetic, ONO-5163 (etelcalcetide) in Japanese hemodialysis patients with secondary hyperparathyroidism : results of a placebo controlled phase III study [abstract no. MP361]. Nephrol Dial Transplant. 2016;31(Suppl 1):i460.Google Scholar
  25. 25.
    Martin K, Block G, Cheng S, et al. Comparison of the efficacy and safety of intravenous (IV) etelcalcetide (AMG 416) and oral cinacalcet (CIN) in patients on hemodialysis (HD) with secondary hyperparathyroidism (sHPT) [abstract no. SA-PO1115]. J Am Soc Nephrol. 2015;26:B9.Google Scholar
  26. 26.
    Bell G, Huang S, Martin KJ, et al. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin. 2015;31(5):943–52.CrossRefPubMedGoogle Scholar
  27. 27.
    Bushinsky DA, Block GA, Martin KJ, et al. Treatment of secondary hyperparathyroidism: results of a phase 2 trial evaluating an intravenous peptide agonist of the calcium-sensing receptor. Am J Nephrol. 2015;42(5):379–88.CrossRefPubMedGoogle Scholar
  28. 28.
    European Medicines Agency. Parsabiv: summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 28 Nov 2016.

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations